Michael Jain, Oncologist at Moffitt Cancer Center, shared a post on X about a recent article by Snegha Ananth et al. published in Blood Advances:
“HLH (‘IEC-HS’) is hard to distinguish from CRS and other diagnoses after CAR T cells, Also, cytopenias (ICAHT) are common after CAR T and stem cell boost is the only known effective solution.
Interestingly, boost was seen to fuel the fire of IEC-HS here.”
Title: Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy
Authors: Snegha Ananth, Nancy Eunice Torres, Bita Sahaf, Lekha Mikkilineni, Sebastian Fernandez-Pol, Darren Salmi, Robert Negrin, Parveen Shiraz, Melody Smith, Sushma Bharadwaj, Wen-Kai Weng, Vanessa E. Kennedy, Saurabh Dahiya, Lori Muffly, David Miklos, Matthew J. Frank, Hitomi Hosoya, Surbhi Sidana
Read the Full Article on Blood Advances
More posts featuring Michael Jain.